



THE BUFFALO NEWS

BUFFALONEWS.COM

Copyright 2018

SATURDAY, JANUARY 13, 2018

Serving Western New York since 1880

FINAL EDITION

Trump sets a deadline to amend Iran deal

*Says U.S. will withdraw
unless 'flaws' are fixed*

By CAROL MORELLO
AND ANNE GEARAN

WASHINGTON POST

WASHINGTON – President Trump on Friday kept alive the Iran nuclear deal he detests by waiving sanctions for the third time, but he said he will not grant another reprieve unless the agreement is amended to permanently block a potential pathway for Iran to build nuclear weapons.

In conjunction with the waivers, the Treasury Department placed sanctions on 14 people and entities for alleged offenses unrelated to Iran's nuclear industry. The new measures concern human rights abuses and censorship in Iran and the arming of groups throughout the region.

Trump's decision avoided placing the United States in violation of the commitments it made in the landmark 2015 deal. But he affirmed his willingness to withdraw from it in a few months unless changes are made.

"Despite my strong inclination, I have not yet withdrawn the United States from the Iran nuclear deal," Trump said in a statement. "Instead, I have outlined two possible paths forward: either fix the deal's disastrous flaws, or the United States will withdraw."

Critics of the deal deemed the president's decision "an opportunity to do better," as Sen. Bob Corker, R-Tenn., chairman of the Senate Foreign Relations Committee, called it.

But supporters expressed skepticism that the deal will survive in its current form. Trita Parsi, head of the National Iranian American Council, called it a "temporary stay of execution."

"In a nutshell, he's saying, 'Kill the deal with me, or we'll kill it alone,'" said Robert Malley, who worked on the National Security Council under President Barack Obama.

Trump blamed Iran for a litany of alleged malign activities, including support for terrorist groups and the "murderous regime" of Syrian President Bashar al-Assad, and torture, mass arrests and oppression at home.

Trump said his strategy for confronting Iran through sanctions and support for Iranian political freedom "stands in stark contrast to the policy and actions of the previous administration."

"President Obama failed to act as the Iranian people took to the streets in 2009. He turned a blind eye as Iran built and tested dangerous missiles and exported terror. He curried favor with the Iranian regime in order to push through the disastrously flawed Iran nuclear deal," he said.

Iranian officials warned that a U.S. withdrawal from the deal would spell its doom.

Foreign Minister Mohammad Javad Zarif said on Twitter that "Trump's policy &

See **Iran** on Page A3



Sharon Cantillon/Bufallo News

NOT YOUR TYPICAL JANUARY DAY

For fans of topsy-turvy weather, Friday offered everything, from flooding and fog to freezing rain that turned to snow – just in time for the evening commute. *Story, Page C1*

President's slur dismays area's African immigrants



*"That's not the United States."
– Gysma Kueny, immigrant
from South Sudan*



*"... our president, whom I did not vote for,
is a racist and a very toxic one."
– Makau Mutua, immigrant from Kenya, former
dean of the University at Buffalo School of Law*



*"The president's profanity I can only
call this shameful and nonsense."
– Antonios Yohannes, immigrant
from Eritrea*



*"We don't have to look very far to see what the
impacts of immigrants and refugees are."
– Mustafa Ali, immigrant
from Somalia*

Photos by Derek Gee/Bufallo News

ANALYSIS

White House words inflame nation's racial tensions

By PETER BAKER

NEW YORK TIMES

WASHINGTON – As he signed a proclamation marking the holiday next week honoring the Rev. Martin Luther King Jr., President Trump on Friday recalled the civil rights leader's message that "no matter what the color of our skin or the place of our birth, we are created equal by God."

Then came the questions from reporters.

"Mr. President, are you a racist?"

He did not answer and instead headed for the door.

It is a question many were asking after the latest charged

See **Trump** on Page A10

**Inside: PORN STAR REPORT-
EDLY WAS PAID TO STAY QUIET
ABOUT TRUMP. PAGE A5**

Resettled residents say Trump's comments go against America's philosophy, values

By MAKI BECKER

NEWS STAFF REPORTER

Gysma Kueny is upset.

Those words that President Trump allegedly used to describe immigrants like herself and the countries they came from and are not what she believes America is about.

"That's not the United States," she said.

She proudly showed off her stall at the West Side Bazaar on Grant Street, a business incubator started by the Westminister Economic Development Initia-

tive where resettled refugees sell delicacies from their home countries as well as clothes, jewelry and other gifts.

Kueny, who is from South Sudan, offers an array of colorful shirts, handmade bracelets and necklaces, shea butter and black soap at the market popular with immigrants and hipster food enthusiasts.

"That's how we know America," she said of the lively lunch scene Friday at the bazaar.

Across Buffalo, a city that's no

See **Immigrants** on Page A10

Alzheimer's research suffers significant setbacks

Pfizer ends its efforts to develop new drugs

By CAROLYN Y. JOHNSON

WASHINGTON POST

WASHINGTON – The first days of 2018 have been a bleak reminder of how tough it is to develop drugs for some of the world's most frightening diseases, which rob people of their memories, abilities and per-

sonalities.

In the span of one week, pharma giant Pfizer announced it was ending its internal efforts to develop new drugs for Alzheimer's and Parkinson's disease. Axovant Sciences announced that its experimental drug, which late last year failed an Alzheimer's trial, had also failed to treat a different form of dementia.

A day later, a leading medical journal published an account of yet another experimental drug that

failed to prevent cognitive decline in people with mild to moderate Alzheimer's disease.

These setbacks pile on to an already depressing situation: more than 400 failed clinical trials since the last Alzheimer's drug – which only treats the symptoms of the disease, temporarily – was approved more than a decade ago.

"If you think it's been a bad week, it's been a bad 14 years. It's 14 years since the last new drug

was approved by the FDA and the string of failures this week is nothing new and not unexpected," said David Bennett, director of the Rush Alzheimer's Disease Center in Chicago.

"I view Pfizer getting out of the Alzheimer's business as not a good thing for the field, but that doesn't mean that I have a strong recommendation for what Pfizer should

See **Alzheimer's** on Page A3

INDEX

Business C6
Comics D4
Car Talk D3
Crossword B10, B11
City & Region C1
Dear Abby D3
Classified B8
Letters A9

Life & Arts D1
Lotteries C2
Obituaries C4
Opinion A8

Picture Page D6
Scoreboard B7
Sports B1
Television D3



WEATHER

Snow and much colder. High 13,
low 2. Details on Page C8.



\$1.00

To subscribe,
call (716) 842-1111